Bill & Melinda Gates Foundation Trust decreased its stake in Microsoft Corp (MSFT) by 50% based on its latest 2019Q1 regulatory filing with the SEC. Bill & Melinda Gates Foundation Trust sold 8.00M shares as the company’s stock rose 6.56% . The hedge fund held 8.00M shares of the prepackaged software company at the end of 2019Q1, valued at $943.52M, down from 16.00 million at the end of the previous reported quarter. Bill & Melinda Gates Foundation Trust who had been investing in Microsoft Corp for a number of months, seems to be less bullish one the $ market cap company. The stock increased 1.83% or $2.45 during the last trading session, reaching $136.13. About 25.03 million shares traded or 2.63% up from the average. Microsoft Corporation (NASDAQ:MSFT) has risen 29.33% since August 18, 2018 and is uptrending. It has outperformed by 29.33% the S&P500. Some Historical MSFT News: 14/03/2018 – Monaco Joins the Enterprise Ethereum Alliance; 30/05/2018 – Sabre Joins Forces with Microsoft to Reimagine the Business of Travel; 17/04/2018 – Tech firms, including Microsoft, Facebook, vow not to aid government cyber attacks; 27/03/2018 – Starr Companies Announces Agreement with SkyWatch for Aviation lnsureds; 19/03/2018 – White House chief of staff John Kelly has appointed former Microsoft and General Motors executive Chris Liddell to be his deputy in charge of policy; 16/05/2018 – Regina Leader: Microsoft planning low-cost Surface tablet line to take on iPad; 10/04/2018 – C3 IoT and Microsoft Announce Strategic Partnership to Accelerate AI in the Enterprise; 12/03/2018 – WANdisco Approved to Sell Data Platform in Microsoft Bundle; 29/05/2018 – Salesforce quarterly revenue rises 25.4 pct; 07/03/2018 – DocuSign picks banks for potential IPO in April
Kahn Brothers Group Inc increased its stake in Glaxosmithkline (GSK) by 1.24% based on its latest 2019Q1 regulatory filing with the SEC. Kahn Brothers Group Inc bought 15,610 shares as the company’s stock rose 2.15% . The hedge fund held 1.28 million shares of the major pharmaceuticals company at the end of 2019Q1, valued at $53.35 billion, up from 1.26M at the end of the previous reported quarter. Kahn Brothers Group Inc who had been investing in Glaxosmithkline for a number of months, seems to be bullish on the $99.56 billion market cap company. The stock increased 0.58% or $0.23 during the last trading session, reaching $40.19. About 1.37M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 0.49% since August 18, 2018 and is uptrending. It has outperformed by 0.49% the S&P500. Some Historical GSK News: 29/05/2018 – GlaxoSmithKline Files Application to Japanese Regulator For Trelegy Ellipta; 24/05/2018 – GSK May Look at Merger Options for Indian Unit -The Economic Times; 18/04/2018 – GSK IMPACT STUDY SHOWS BENEFITS OF TRELEGY ELLIPTA; 25/04/2018 – HPV Vaccine Market 2022 Demand, Key Players- Merck and Co., GlaxoSmithKline; 22/03/2018 – GSK’s pursuit of Pfizer consumer unit need not be a costly move; 11/04/2018 – Fitch Affirms Sr. Unsecured Instrument Rating at ‘A’ for Debt Issued by GlaxoSmithKline Capital PLC and GlaxoSmithKline Capital Inc; 18/04/2018 – GSK grabs Roche cancer expert to lead pharma pipeline deals; 25/04/2018 – GlaxoSmithKline 1Q Adjusted Op Pft GBP1.92B; 22/03/2018 – GSK advances in Pfizer consumer health auction as Reckitt quits; 27/03/2018 – Yahoo! Finance: Nestle, other food groups likely suitors for GSK’s Horlicks
More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Streetinsider.com which released: “GSK raises 2019 earnings expectations after standout quarter for Shingrix – StreetInsider.com” on July 24, 2019, also Bizjournals.com with their article: “GSK, Pfizer complete deal to combine consumer health brands – Philadelphia Business Journal” published on August 01, 2019, Finance.Yahoo.com published: “Kahn Brothers’ Top 6 Buys in the 2nd Quarter – Yahoo Finance” on August 06, 2019. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Seekingalpha.com and their article: “Glaxo’s Shingrix conditionally OK’d in China – Seeking Alpha” published on May 22, 2019 as well as Seekingalpha.com‘s news article titled: “Glaxo launches late-stage development of RA med otilimab – Seeking Alpha” with publication date: July 03, 2019.
Kahn Brothers Group Inc, which manages about $640.04B US Long portfolio, decreased its stake in Exxon Mobile (NYSE:XOM) by 248 shares to 19,574 shares, valued at $1.58B in 2019Q1, according to the filing. It also reduced its holding in American Tel & Tel by 50 shares in the quarter, leaving it with 12,587 shares, and cut its stake in Seaboard Corp (NYSEMKT:SEB).
Investors sentiment decreased to 0.91 in Q1 2019. Its down 0.03, from 0.94 in 2018Q4. It dropped, as 64 investors sold MSFT shares while 922 reduced holdings. 159 funds opened positions while 742 raised stakes. 5.41 billion shares or 1.21% less from 5.48 billion shares in 2018Q4 were reported. Jensen Inv Mngmt Incorporated holds 6.06% in Microsoft Corporation (NASDAQ:MSFT) or 4.32 million shares. 1.00M are held by Hitchwood Cap Lp. Clough Capital Prtn LP holds 2.96% or 287,000 shares. Kepos Cap LP reported 23,500 shares. Nordea Inv Mgmt Ab reported 8.87 million shares. Bahl & Gaynor has 4.63% invested in Microsoft Corporation (NASDAQ:MSFT) for 4.28M shares. Weiss Multi has invested 0.33% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Telemus Cap Ltd accumulated 168,765 shares. Price T Rowe Associate Inc Md holds 3.36% of its portfolio in Microsoft Corporation (NASDAQ:MSFT) for 193.86M shares. Hs Management Prns Ltd Limited Liability Company owns 737,526 shares for 2.94% of their portfolio. Stone Ridge Asset Mgmt Ltd Liability accumulated 0.23% or 34,340 shares. New England Invest Retirement Gp Incorporated invested in 1,750 shares. New York-based Alkeon Mgmt Limited Liability Corporation has invested 1.33% in Microsoft Corporation (NASDAQ:MSFT). Pggm Invs owns 561,155 shares. 3G Capital Ltd Partnership stated it has 12.62% of its portfolio in Microsoft Corporation (NASDAQ:MSFT).
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.